


50771 D/28  
TEIJIN KK

B05 (B01)

TEIJ 26.10.79  
\*JS 6061-351

26.10.79-JP-137771 (26.05.81) A61k-31/59 C07c-172  
1-Alpha, 25-di:hydroxy-24-oxo:cholecalciferol derive -  
exhibit vitamin/D<sub>3</sub> pharmacological activities. prep'd. from  
24-oxo-cholesta-5,7-diene cpds.

1a,25-Dihydroxy-24-oxocholecalciferols of formula (I)  
are new:



(R', R<sup>2</sup> and R<sup>3</sup> = H  
or hydroxy protecting  
gp. (pref. 1-12C ali-  
phatic or aromatic  
acyl, trialkylsilyl, 2-  
tetrahydropyranyl, or  
2-tetrahydrofuryl)).

B(1-D2, 3-G). 2


109

USE/ADVANTAGE

(I) exhibit vitamin D<sub>3</sub>-like pharmacological activities.  
On reduction of the 24-oxo, (I) are converted into 1a, 24,  
25-trihydroxyvitamin D<sub>3</sub> as active vitamin D<sub>3</sub>.

PREPARATION

(I) are prep'd. by irradiating 1a,25-dihydroxy-24-oxo-  
cholesta-5,7-dienes (II) with ultraviolet rays to yield 1a,25-  
dihydroxy-24-oxoprevitamins D<sub>3</sub>, isomerising the latter  
with thermal energy. If required followed by removal of the  
hydroxy protecting gp.



J56061351+

The UV rays pref. have wavelength 200-360 nm, esp. 260-  
310 nm. The reaction is conducted in an inert solvent-  
including hydrocarbons and halohydrocarbons (e.g. hexane,  
heptane, PhH, PhMe, xylene, PhCl), ethers (e.g. Et<sub>2</sub>O, THF,  
dioxane), and alcohols (e.g. MeOH, EtOH, PrOH) at a temp.  
of -20°C to 120°C, pref. -10°C to 50°C. The subsequent  
thermal isomerisation is carried out at 20-120°C, pref.  
40-100°C in the inert solvent.

EXAMPLE


A soln. of 70 mg 1a,3β,25-trihydroxy-24-oxocholesta-5,7-  
diene dissolved in a mixt. of 50 mg deoxygenated EtOH and  
500 ml Et<sub>2</sub>O was irradiated with a 200W lamp surrounded by  
a Vycor filter at 10-20°C with stirring for 6 hrs. The  
cold soln. was evapd. in *vacuo* at 30°C, and the residue was  
dissolved in 250 ml deoxygenated PhH and refluxed under  
heating for 2.5 hr. After the reaction completion, the mixt.  
was evapd. in *vacuo*, and the resulting residue was chrom-  
atographed on a thin layer of silica gel preliminarily trea-  
ted with 2% AgNO<sub>3</sub>-MeCN (solvent:CHCl<sub>3</sub>-MeOH) and of sil-  
ica gel (PhH-Me<sub>2</sub>CO) to give 10.8 mg 1a,25-dihydroxy-24-  
oxovitamin D<sub>3</sub>, mp. 91-93.5°C. (6ppW52)

J56061351

50772 D/28  
SAGAMI CHEM RES CENTREB03  
SAGA 24.10.79  
\*JS 6061-352

24.10.79-JP-125485 (26.05.81) C07c-101/77 C07d-205/08  
3-Hydroxy-β-lactam cpds. can be prep'd. economically -  
and are used in DOPA prep'n. used in antiparkinson  
treatment:

3-Hydroxy-β-lactam cpds. of formula (I) are new:



(R' and R'' = H, lower alkyl, benzyl or acyl, or R' and R''  
taken together may form alkylene;  
R' = alkyl, aryl or heteroaromatic gp.;  
X = H, benzyl or tosyl).



USE/ADVANTAGE

(I) can be converted into DOPA (useful as antiparkinson-

B(6-A2, 7-D1). 2

110

ism agent) on reaction with NaN<sub>3</sub>, cleavage of the β-lactam  
ring, and acid treatment. (I) can be prep'd. from cheap  
raw material.

PREPARATION

(Y is not defined but probably halogen).

Step (A) is carried out in a solvent, e.g. PhH, PhMe, THF,  
CH<sub>2</sub>Cl<sub>2</sub>, in presence of a tert. amine, e.g. Et<sub>3</sub>N, Pr<sub>2</sub>N,  
Bu<sub>3</sub>N, pyridine, N-methylpiperidine, N-methylpyrrolidine  
DBU, at -78°C to 100°C.

J56061352+

Step (B) comprises hydrogenolysis with Pd catalyst (e.g. Pd black, Pd-C) in a solvent (e.g. MeOH, EtOH, CH<sub>2</sub>Cl<sub>2</sub>, CHCl<sub>3</sub>, PhH, PhMe, THF, MeCN, DMF) at room temp. to 150°C, pref. 50-100°C.

Step (C) comprises tosylation with p-TsCl in presence of a tert-amine in an aprotic solvent (e.g. CH<sub>2</sub>Cl<sub>2</sub>, CHCl<sub>3</sub>, PhH, PhMe, THF, MeCN, Me<sub>2</sub>CO, DMF, DMSO) at -30°C to 100°C.


EXAMPLE

T. a soln. of 5.00 g 3,4-dimethoxybenzylideneaniline and 2.50 g Et<sub>3</sub>N in 50 ml PhH was dropwise added slowly a soln. of 4.60 g benzyloxyacetyl chloride in 50 ml PhH under ice cooling. The reaction mixt. was gradually warmed up to room temp., stirred for 15 hrs., washed with water, dried on MgSO<sub>4</sub>, and evapd. in vacuo to give 8.18 g light yellow oil. This was chromatographed on silica gel and eluted with n-hexane-EtOAc (4 : 1) to give 4.16 g cis-isomer of 1-phenyl-3-benzyloxy-4-(3,4-dimethoxyphenyl)azetidin-2-one as white crystals, m. pt. 130-133°C, and 2.38 g trans-isomer as a colourless oil, n<sub>D</sub><sup>24.0</sup> : 1.6018. (1OppW52).

J 56061352

50774 D/28 B03 C02 E13 MITSUBISHI CHEM IND KK 23.10.79 23.10.79-JP-136740 (26.05.81) C07d-211/90 C07d-213/80 Nicotinic acid derivs. - used as agrochemicals, drugs and chemical intermediates

Nicotinic acid derivs. of formula (I) are new:



(I) (R¹ = lower alkyl (e.g. Me, Et, n-Pr, i-Pr, n-Bu, i-Bu, s-Bu, t-Bu); R² = H, lower alkyl or aryl (e.g. phenyl, tolyl); R³OOC = lower alkoxy carbonyl (e.g. MeOCO-, EtOCO-, n-PrOCO-, i-PrOCO-) or COOH).



X = lower alkoxy carbonyl (e.g. MeOCO-, EtOCO-, n-PrOCO-, i-PrOCO-) or COOH.

USE

(I) are utilized as agrochemicals or drugs or as raw material in production of various chemicals. (I) can be converted into nicotinic acid or its esters by removal of -SR¹ on hydrogenolysis with Raney Ni catalyst.

PREPARATION

BC(7-D4) E(7-D4) N(5-A). 1



(Z⁻ = anion (e.g. halogen ion, ClO₄⁻, BF₄⁻, SbF₆⁻, SbCl₆⁻, AlCl₄⁻); R¹ = lower alkyl).

DETAILS

(II) has been described in J 48096564.

The reaction is carried out in a solvent, e.g. CH<sub>2</sub>Cl<sub>2</sub>, CHCl<sub>3</sub>, dimethoxyethane, DMF, MeOH, pref. in presence of a base, e.g. NaH, t-BuOK, at -100°C to the reflux temp. of a

J 56061354.

the solvent used, pref. room temp. to 100°C, for a per iod of 0.1-10 hrs., pref. 0.5-5 hrs.

The subsequent dehydration is achieved by allowing (IV) to stand in a halogenohydrocarbon solvent, e.g. ClCH<sub>2</sub>, CCl<sub>4</sub>, fluorohydrocarbon, perfluorohydrocarbon, at 0°C to the reflux temp. of the solvent used, pref. room temp., for a period of 3-24 hrs., pref. 10-15 hrs.

EXAMPLE

A mixt. of tri-t-butylthiocycloopenonium perchlorate (1 mmole, 403 mg.) and methyl α-aminopropionate (2 mmole) in 40 ml. DMF is allowed to stand at 80°C in presence of NaH (3 mmole) for 1 hr. Water is added, and the mixt. is extracted with hexane. The extract is dried on Na<sub>2</sub>SO<sub>4</sub> and evapd., the resid. is chromatographed on silica gel to give methyl 2,3-di-t-butylthio-1,6-dihydronicotinate (72% yield).

This is dissolved in 10 ml. CCl<sub>4</sub> and allowed to stand under air for 2 hrs. to give methyl 2,3-di-t-butylthio-nicotinate in qu. titative yield. (1OppW52)

J 56061354